Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

A Study Of Celecoxib Versus Diclofenac In Patients With Ankylosing Spondylitis

18 augusti 2015 uppdaterad av: Pfizer

A Twelve Week, Randomized, Double Blind Parallel Group Study Of Two Doses Of Celecoxib Compared To Diclofenac In Patients With Ankylosing Spondylitis

A clinical trial to assess the effect of celecoxib 200 milligrams (mg) once daily and 400 milligrams (mg) once daily compared to diclofenac three times daily in the treatment of Ankylosing Spondylitis (AS) for 12 weeks. This will be used to confirm the results of a prior 6 week trial.

Studieöversikt

Status

Avslutad

Betingelser

Intervention / Behandling

Studietyp

Interventionell

Inskrivning (Faktisk)

330

Fas

  • Fas 4

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

  • Norge
      • Bekkestua, Norge, 1357
        • Bekkestua legesenter
      • Bergen, Norge, 5004
        • Dr. Johannessen Kontor
      • Bergen, Norge, 5838
        • Dr.Wiigs kontor
      • Bodø, Norge, 8006
        • Nordland Medisinske Senter
      • Bærum Postterminal, Norge, 1306
        • Martina Hansens Hospital
      • Drammen, Norge, 3004
        • Sykehuset Buskerud HF
      • Gamle Fredrikstad, Norge, 1632
        • Lægene på Kongens torv
      • Hamar, Norge, 2300
        • Centre For Clinical Trials
      • Harstad, Norge, 9480
        • Harstad sykehus
      • Haugesund, Norge, 5513
        • Haugesund sanitetsforenings revmatismesykehus
      • Horten, Norge, 3188
        • Horten legesenter
      • Jessheim, Norge, 2050
        • Solli Klinikk AS
      • Kongsvinger, Norge, 2226
        • Kongsvinger sykehus HF
      • Kristiansand, Norge, 4604
        • Vest-Agder sentralsykehus
      • Kristiansand, Norge, 4610
        • Dr. Svensens kontor
      • Lena, Norge, 2850
        • Lensbygda Legekontor
      • Levanger, Norge, 7600
        • Helse Nord-Trøndelag HF, Sykehuset Levanger
      • Lillehammer, Norge, 2609
        • LSF Reumatismesykehus
      • Mo I Rana, Norge, 8607
        • Helgelandssykehuset HF
      • Oslo, Norge, 0027
        • Rikshospitalet
      • Oslo, Norge, 0580
        • Økernlegene
      • Oslo, Norge, N-0319
        • Diakonhjemmet Hospital
      • Skien, Norge, 3722
        • Betanien Hospital
      • Tiller, Norge, 7092
        • Rosten legesenter
      • Tromsø, Norge, 9038
        • Universitetssykehuset Nord-Norge HF
      • Trondheim, Norge, 7006
        • St.Olavs Hospital
      • Ålesund, Norge, 6026
        • Ålesund Sykehus

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 75 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Male or female, 18 to 75 years of age, inclusive.
  • Clinical diagnosis of ankylosing spondylitis:
  • Willing to stop existing NSAID/COX-2 inhibitor treatment for up to two weeks.
  • Having given written informed consent to participate in the trial.
  • Pain intensity ≥ 40 mm on the visual analog scale, worsening by at least 30 % compared to that recorded at the screening visit.
  • Last administration of analgesic without anti-inflammatory activity is ≥ 8 h, the last administration of long-acting NSAIDs is ≥ 72 h

Exclusion Criteria:

  • Patients with acute peripheral articular disease (defined by the onset within 4 weeks prior to visit
  • Known inflammatory enteropathy (e.g. ulcerative colitis, Crohn's disease).
  • Ongoing extra-articular signs (e.g. cardiac involvement).
  • Current painful vertebral compression.
  • Requirement to start physiotherapy, re-education or manipulation
  • History of clinical gastroduodenal ulcer in the year preceding inclusion, confirmed by endoscopy; continuing gastro-intestinal bleeding.
  • Cardiac failure or known renal insufficiency that could be affected by study medication, chronic or acute hepatic insufficiency, significant coagulation disorders or history of asthma.
  • Current or history of malignancy (except: patients having a basal cell carcinoma or other malignancy operated on and in remission for 5 years before inclusion in the trial).
  • Pregnancy, women of childbearing potential not using adequate contraceptive methods or nursing mothers.
  • Subject who has evidence of alcohol or drug abuse.
  • Participation in any other clinical study within 30 days prior to the screening visit.
  • Any condition that would prevent the patient from entering the study, according to the investigator's judgment.
  • Known hypersensitivity to celecoxib, sulphonamides or any NSAID (including salicylic acid).
  • Taking the following medications: Muscle relaxants, hypnotic, anxiolytics, sedatives, tranquillizers or antidepressants (unless stable for 2 weeks before screening and continuing throughout the trial), NSAIDs or COX-2 inhibitors other than study medication, acetylsalicylic acid (ASA) > 160 mg /day, anti-coagulants, ticlopidine, lithium, anti-TNF agents or methotrexate > 15 mg/week (Note: ASA ≤ 160 mg/day for cardioprotection is permitted), Use of oral or systemic analgesic medication, except from paracetamol, within 3 days of study entry and through the study, Corticosteroids (PO/IM/IV/IA) in the 6 weeks preceding inclusion in the trial, Anti-ulcer medication including chronic (daily or almost daily) use of antacids [Note: Occasional use of antacids during the study will be permitted.]
  • Change in dose of a slow-acting drug (e.g. sulfasalazin, methotrexate) in the past 60 days preceding inclusion in the trial.
  • Taking paracetamol > 2000 mg/day (including during the screening period).

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Aktiv komparator: Celecoxib 200 milligrams mg QD
celecoxib 200 milligrams (mg) once a day (QD)
Läkemedel: Celecoxib 200 milligrams
Celecoxib 200 milligrams once a day
Aktiv komparator: Celexocib 400 mg QD
celecoxib 400 milligrams (mg) once a day (QD)
Läkemedel: Celecoxib 400 milligrams
Celecoxib 400 milligrams once a day
Aktiv komparator: Diclofenac 50 mg TID
diclofenac 50 milligrams (mg) three times a day (TID)
Läkemedel: diclofenac 50 milligrams
diclofenac 50 milligrams three times a day

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in baseline of Patient Global Assessment of Pain Intensity (VAS) at week 12
Tidsram: Baseline, Week 12
Global Pain Intensity score (VAS): is a participant reported assessment of pain on a 0 to 100 millimeter (mm) Visual Analog Scale (VAS) where 0 mm= no pain and 100=most severe pain.
Baseline, Week 12

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Participants Global Assessment of Pain Intensity (VAS)
Tidsram: Weeks 2, 6
Global Pain Intensity score (VAS): is a participant reported assessment of pain on a 0 to 100 millimeter (mm) Visual Analog Scale (VAS) where 0 mm= no pain and 100=most severe pain.
Weeks 2, 6
Bath Ankylosing Spondylitis Functional Index (BASFI)
Tidsram: Weeks 2, 6
BASFI is a validated self assessment tool that determines the degree of functional limitation in AS. Utilizing a VAS of 0-10 (0 = easy, 10 = impossible), participants answered 10 questions assessing their ability in completing normal daily activities or physically demanding activities. The BASFI score is a mean score of the 10 questions.
Weeks 2, 6
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
Tidsram: Weeks 2, 6
BASDAI is a validated self assessment tool used to determine disease activity in participant with Ankylosing Spondylitis (AS). Utilizing a Visual Analog Scale (VAS) of 0-10 (0=none and 10=very severe) participant's answered 6 questions measuring discomfort, pain and fatigue. The final BASDAI score averages the individual assessments for a final score range of 0-10
Weeks 2, 6
Participants and Physicians Global Assessment of Disease Activity
Tidsram: Weeks 2, 6, 12
Participants are asked at each visit the following questions: Taking everything into account how do you assess the activity of your disease in the last 2 days on a scale where: 0=disease inactive with no symptoms and 100=disease extremely active?
Weeks 2, 6, 12
Participants and Physicians Global Assessment of Treatment
Tidsram: Week 12
The patients will be asked up to four global questions about safety and efficacy of the trial medication and about their current disease status. Responses are done on a 5 point scale where 0=no effect, 1=poor effect, 2=moderate effect, 3=good effect, and 4=excellent. At the same visits the investigator will be asked to do his/her own judgment of the efficacy and tolerance of the treatment (excellent, good, moderate, poor).
Week 12
Participants Consumption of Rescue Medication
Tidsram: Baseline, Weeks 2, 6, 12
Participant consumption of rescue medication (paracetamol) calculated at each individual visit (except from the screening visit) by counting returned tablets versus tablets dispensed at the previous visit.
Baseline, Weeks 2, 6, 12

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Pfizer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 september 2002

Primärt slutförande (Faktisk)

1 november 2004

Avslutad studie (Faktisk)

1 november 2004

Studieregistreringsdatum

Först inskickad

18 juni 2015

Först inskickad som uppfyllde QC-kriterierna

18 augusti 2015

Första postat (Uppskatta)

19 augusti 2015

Uppdateringar av studier

Senaste uppdatering publicerad (Uppskatta)

19 augusti 2015

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

18 augusti 2015

Senast verifierad

1 augusti 2015

Mer information

Termer relaterade till denna studie

Nyckelord

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • COXA-0508-247
  • A3191099 (Annan identifierare: Alias Study Number)

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera